NATCO Pharma
NSEI:NATCOPHARM Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 67 Fair Values set on narratives written by author
WA
Consensus Narrative from 12 Analysts
Future Revenue Will Decline As Competition Erodes Revlimid Pricing And R&D Costs Compress Margins
Key Takeaways Uncertainty in pricing and revenue from Revlimid could impact net margins and limit R&D expenditure. Lack of launch timelines and litigation outcomes may cause volatility and delay revenue growth from key pipeline products.
View narrative₹1.35k
FV
39.7% undervalued intrinsic discount0.53%
Revenue growth p.a.
2users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
10 days ago author updated this narrative